Anacalypsis Therapeutics
About
Anacalypsis Therapeutics is an innovative biotechnology company focused on developing next-generation LRRK2-based precision therapeutics for neurodegenerative diseases, including Parkinson’s and Alzheimer’s. Our lead program, AT001, is a stapled peptide targeting key pathological mechanisms in Parkinson’s disease, with both broad and genetically stratified (G2019S LRRK2) development strategies.
Our multidisciplinary team combines expertise in neuroscience, translational pharmacology, and biomarker development. We employ advanced in vitro and in vivo models, CSF and imaging biomarkers, and precision medicine approaches to accelerate the path from discovery to clinic.
Anacalypsis Therapeutics actively seeks academic, clinical, and industrial partners for Horizon Europe Health projects related to neurodegeneration, biomarker validation, CNS drug delivery, and personalized medicine. We bring strong translational capabilities, preclinical models, and experience in early-stage therapeutic development to collaborative consortia.
Biotechnology and/or Biopharmaceutical
Representatives
CEO & Co-founder
Anacalypsis Therapeutics